These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8852455)

  • 1. Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer.
    Rosenecker J; Harms KH; Bertele RM; Pohl-Koppe A; v Mutius E; Adam D; Nicolai T
    Infection; 1996; 24(1):5-8. PubMed ID: 8852455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors.
    Piedra PA; Poveda GA; Ramsey B; McCoy K; Hiatt PW
    Pediatrics; 1998 Jun; 101(6):1013-9. PubMed ID: 9606228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the respiratory epithelium of normals and individuals with cystic fibrosis for the presence of adenovirus E1a sequences relevant to the use of E1a- adenovirus vectors for gene therapy for the respiratory manifestations of cystic fibrosis.
    Eissa NT; Chu CS; Danel C; Crystal RG
    Hum Gene Ther; 1994 Sep; 5(9):1105-14. PubMed ID: 7833370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung.
    Yei S; Mittereder N; Tang K; O'Sullivan C; Trapnell BC
    Gene Ther; 1994 May; 1(3):192-200. PubMed ID: 7584081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Impact of Natural IgM on Adenovirus Type 5 Gene Therapy Vectors.
    Xu Z; Tian J; Harmon AW; Byrnes AP
    Methods Mol Biol; 2017; 1643():187-196. PubMed ID: 28667539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
    Harvey BG; Hackett NR; El-Sawy T; Rosengart TK; Hirschowitz EA; Lieberman MD; Lesser ML; Crystal RG
    J Virol; 1999 Aug; 73(8):6729-42. PubMed ID: 10400771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis.
    Cowan RG; Winnie GB
    J Clin Immunol; 1993 Sep; 13(5):359-70. PubMed ID: 8245182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
    Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP
    Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
    Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML
    Hum Gene Ther; 2006 Apr; 17(4):440-7. PubMed ID: 16610931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies in serum and sputum from patients with cystic fibrosis.
    Schiøtz PO; Egeskjold EM; Høiby N; Permin H
    Acta Pathol Microbiol Scand C; 1979 Oct; 87(5):319-24. PubMed ID: 117671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.
    Mastrangeli A; Harvey BG; Yao J; Wolff G; Kovesdi I; Crystal RG; Falck-Pedersen E
    Hum Gene Ther; 1996 Jan; 7(1):79-87. PubMed ID: 8825871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of IgG serum levels in cystic fibrosis].
    Vázquez Cordero C; Sánchez Obregón M; Molinuevo Alvaro J; Larrea Rementería F; Vitoria Cormenzana JC; Sojo Aguirre A
    An Esp Pediatr; 1988 Apr; 28(4):321-4. PubMed ID: 3400941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function.
    Winnie GB; Cowan RG
    Pediatr Pulmonol; 1991; 10(2):92-100. PubMed ID: 1903199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.
    Petersen TD; Ciofu O; Pressler T; Giwercman B; Pedersen SS; Høiby N
    Thorax; 1996 Jul; 51(7):733-8. PubMed ID: 8882082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescent antibody responses to adenoviruses in humans.
    Ariyawansa JP; Tobin JO
    J Clin Pathol; 1976 May; 29(5):411-6. PubMed ID: 180061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis.
    Greally P; Hussain MJ; Vergani D; Price JF
    Arch Dis Child; 1993 Jun; 68(6):785-7. PubMed ID: 8333775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.
    Rooney CP; Denning GM; Davis BP; Flaherty DM; Chiorini JA; Zabner J
    J Virol; 2002 Oct; 76(20):10437-43. PubMed ID: 12239320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans.
    Grubb BR; Pickles RJ; Ye H; Yankaskas JR; Vick RN; Engelhardt JF; Wilson JM; Johnson LG; Boucher RC
    Nature; 1994 Oct; 371(6500):802-6. PubMed ID: 7523956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity.
    Schulick AH; Vassalli G; Dunn PF; Dong G; Rade JJ; Zamarron C; Dichek DA
    J Clin Invest; 1997 Jan; 99(2):209-19. PubMed ID: 9005989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
    Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
    Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.